00:36 , Jun 8, 2019 |  BioCentury  |  Product Development

ASCO 2019 sessions provide guidance on expanding patient pools for clinical trials

Two sessions at this year's American Society of Clinical Oncology meeting gave drug developers a glimpse of how to match more patients to clinical trials by broadening eligibility criteria and encouraging trial enrollment in community...
22:04 , Jun 3, 2019 |  BC Extra  |  Clinical News

Following promising ASCO readout for AMG 510, Amgen looks to identify more KRAS-mutant patients

After making a strong showing at ASCO with data for its KRAS inhibitor in non-small cell lung cancer patients, Amgen will now look to expand the program's options for finding trial-eligible patients. Amgen Inc. (NASDAQ:AMGN)...
02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
01:12 , Jun 1, 2019 |  BioCentury  |  Product Development

Clinical trial and regulatory efficiency get help from ctDNA, RWE at ASCO19

This year’s crop of ASCO abstracts show companies are going full bore on pre- and post-market technologies that can speed up development and regulatory timelines. In BioCentury’s analysis of 4,627 abstracts, over 500 feature circulating...
00:28 , May 24, 2019 |  BC Innovations  |  Emerging Company Profile

Anima opens new target space in translational control

Anima Biotech’s answer to undruggable targets is to go after the machinery that turns their mRNA into protein, adding a new approach to the gene regulation tool kit. The strategy should give Anima a leg...
00:06 , May 16, 2019 |  BC Extra  |  Clinical News

May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven

Abstracts were released late Wednesday ahead of the American Society of Clinical Oncology meeting starting May 31 in Chicago. See below for BioCentury's first round of Quick Takes on selected abstracts. Iovance gains on 44%...
17:25 , Apr 22, 2019 |  BC Innovations  |  Distillery Therapeutics

Combined inhibition of EGFR and RAF1 for mutant-KRAS, mutant TP53-driven PDAC

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Cell culture and mouse studies suggest dual inhibition of EGFR and CRAF could help treat KRAS- and p53-mutant pancreatic ductal adenocarcinoma (PDAC). In nine patient-derived KRAS- and p53-mutant PDAC...
13:54 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

Cell-penetrating mini-protein targeting MYC for lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Cell culture and mouse studies suggest a cell-penetrating mini-protein targeting MYC-MYC and MYC-MAX interactions could help treat lung cancer. In three human non-small cell lung cancer (NSCLC) cell lines,...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
18:01 , Apr 5, 2019 |  BC Week In Review  |  Clinical News

Amgen's AMG 510 inhibits tumor growth in mice

Amgen reported the first preclinical data for its small molecule G12C-mutant K-Ras (KRAS) inhibitor, AMG 510, at the American Association for Cancer Research (AACR) meeting in Atlanta. Amgen Inc. (NASDAQ:AMGN) said AMG 510 significantly decreased...